No products in the cart.
Pre-made Rozanolixizumab benchmark antibody ( Whole mAb, anti-FCGRT therapeutic antibody, Anti-FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-498
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Rozanolixizumab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rozanolixizumab (UCB7665) is an investigational humanized monoclonal IgG antibody being developed by UCB for the treatment of myasthenia gravis (MG), a neuromuscular condition thought to be triggered by an autoimmune response.
| Products Name (INN Index) | Pre-Made Rozanolixizumab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody |
|---|---|
| INN Name | Rozanolixizumab |
| Target | FCGRT |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 6fgb:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | UCB |
| Conditions Approved | NA |
| Conditions Active | Chronic inflammatory demyelinating polyradiculoneuropathy,Idiopathic thrombocytopenic purpura,Myasthenia gravis |
| Conditions Discontinued | Immunological disorders |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FCGRT |
| Package |
Previous slide
Next slide
